RA0127

antibody from Oursmab

Targeting: CD6 Tp120

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0127

Provider

Oursmab

Product name

Itolizumab (Biosimilar Reference Antibody) (CD6)

Antibody type

Monoclonal

Description

Itolizumab is a humanized, recombinant monoclonal antibody that uniquely targets the CD6 receptor on T cells. It functions as an immune modulator by binding to the SRCR-1 domain of CD6, thereby interfering with the CD6-ALCAM (Activated Leukocyte Cell Adhesion Molecule) interaction. This action inhibits T-cell activation, proliferation, and migration to inflammatory sites. Itolizumab is notable for being one of the first anti-CD6 antibodies approved for therapeutic use, specifically in India for moderate to severe chronic plaque psoriasis. It is also being investigated for other autoimmune conditions and cytokine storm-associated complications, such as in severe COVID-19.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Itolizumab (Biosimilar Reference Antibody) (CD6)-RA0127-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.